Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NAAA | Q02083 | 10/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6865447 | 0.85 | HDAC3 (0.49) | NPC1RAB9ASMN1; SMN2POLBLMNA | |
| SCHEMBL29278320 | 0.79 | NPC1 (0.57) | NPC1RECQLRAB9ASMN1; SMN2NAAA | |
| SCHEMBL6865270 | 0.79 | HDAC3 (0.54) | NPC1RAB9APOLBLMNA | |
| SCHEMBL4914221 | 0.77 | NPC1 (0.62) | NPC1RECQLRAB9ASMN1; SMN2NAAA | |
| SCHEMBL6865243 | 0.75 | HDAC3 (0.50) | SMN1; SMN2POLBLMNA | |
| SCHEMBL7418194 | 0.75 | HDAC3 (0.61) | SMN1; SMN2LMNA | |
| SCHEMBL16307319 | 0.75 | LMNA (0.53) | NPC1RECQLRAB9ASMN1; SMN2NAAA | |
| SCHEMBL27611273 | 0.75 | NPC1 (0.63) | NPC1RECQLRAB9ASMN1; SMN2NAAA | |
| SCHEMBL3935097 | 0.74 | LMNA (0.56) | NPC1RECQLRAB9ASMN1; SMN2NAAA | |
| SCHEMBL6868580 | 0.74 | HDAC3 (0.49) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6803381-B1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS, ACTING AS ANTAGONISTS OR AGONISTS | HOFFMANN-LA ROCHE INC. | 2004-10-12 | — | — | US | disclosed |
| US-6596743-B2 | Control or prevention of acute and/or chronic neurological disorders | HOFFMANN-LA ROCHE INC. | 2003-07-22 | — | — | US | disclosed |
| US-6462198-B1 | USED IN THE CONTROL OR PREVENTION OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS RESTRICTED BRAIN FUNCTION CAUSED BY BYPASS OPERATIONS OR TRANSPLANTS, POOR BLOOD SUPPLY TO THE BRAIN, SPINAL CORD INJURIES, HEAD INJURIES, HYPOXIA, | HOFFMANN-LA ROCHE INC. | 2002-10-08 | — | — | US | disclosed |
| US-20020091150-A1 | Carbamic acid derivatives | BLEICHER KONRAD (DE) | 2002-07-11 | — | — | US | disclosed |
| EP-1171423-A1 | CARBAMIC ACID DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000063166-A1 | CARBAMIC ACID DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091150-A1 | Carbamic acid derivatives | CHRM1, CHRNA2, CHRM2 | NPC1 2457/4885RECQL 1644/4885RAB9A 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.